Thyroid Dysfunction after Gonadotropin-Releasing Hormone Agonist Administration in Women with Thyroid Autoimmunity

Table 1

Characteristics of the patients, according to groups A and B.

Parameter	Group A (n = 42)	Group B (n = 36)
Age (y)	36 (7)	37 (4)	0.6222
BMI (kg/m^2)	23.5 (4.5)	22.0 (2.0)	0.2732
TSH at T0 (mIU/L)	2.00 (1.11)	1.87 (1.17)	0.7185
TSH at T1 (mIU/L)	2.33 (1.65)	2.14 (1.32)	0.2066
TSH difference T1-T0 (mIU/L)	0.385 (0.99)	0.305 (1.08)	0.2357
Anti-TG Ab^† (n/total)	9/34	2/31	0.0316
Anti-TPO Ab^† (n/total)	8/34	2/31	0.0566
Either antithyroid Ab^† (n/total)	10/34	2/31	0.0172
Endometrial thickness (mm)	8.7 (2.0)	9.0 (1.3)	0.6574
Total dose of estradiol administered (mg)	69.0 (28.5)	71.0 (27.0)	0.8403
Duration of estradiol administration (days)	11 (4)	10 (2)	0.2071
Positive β-hCG test (>5 U/l) (n/total)	11/42	15/36	0.1483

Continuous variables are presented as median and (IQR). ^†Data for some patients were not available in the clinical record. The frequency value is followed by the total number of available cases. Comparison between groups A and B. Significant values are indicated in italics. Patients were divided into two groups according to pretreatment protocol: 42 women received GnRHa (group A) and 36 women were given OCP (group B). None of the enrolled patients had comorbidities such as autoimmune or endocrine diseases in addition to thyroid autoimmunity.